Companies › Zealand Pharma
2 active drug programs in 4 registered trials: 2 Phase 1, 2 Phase 3; Immunology, Other, Gastroenterology; next expected readout Apr 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Glepaglutide | – | Phase 3 | Short Bowel Syndrome (SBS); Short Bowel Syndrome | Sep 2028 |
| ZP9830 | – | Phase 1 | Healthy Volunteers; Plaque Psoriasis | Apr 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06682975 | ZP9830 | Phase 1 | Healthy Volunteers | Other | Aug 2026 |
| NCT07733089 | ZP9830 | Phase 1 | Plaque Psoriasis | Immunology | Apr 2027 |
| NCT07228403 | Glepaglutide | Phase 3 | Short Bowel Syndrome (SBS) | Gastroenterology | Sep 2028 |
| NCT07197944 | Glepaglutide | Phase 3 | Short Bowel Syndrome | Gastroenterology | Oct 2028 |
No annotated target.
–
Forte Biosciences Novadip Biosciences Astria Therapeutics Pacira Pharmaceuticals Onconic Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.